Darifenacin, a new M3 selective receptor antagonist oral treatment in development for overactive bladder (OAB), reduces the number of weekly incontinence episodes by up to 77%1 in an elderly population. Also, darifenacin does not impair cognitive function such as memory, choice reaction time and word recognition, compared to placebo2. This is according to data presented today at the XIXth European Association of Urology (EAU) Congress, Vienna.
